α-Bisabolol

We are α-Bisabolol CAS:515-69-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 515-69-5
Product Name: α-Bisabolol
Other Name:
α-Bisabolol
6-Methyl-2-(4-methyl-3-cyclohexen-1-yl)-5-hepten-2-ol
(2R)-6-Methyl-2-[(1R)-4-methylcyclohex-3-en-1-yl]hept-5-en-2-ol
 
Density: 0.9±0.1 g/cm3
Boiling Point: 314.5±11.0 °C at 760 mmHg
Molecular Formula: C15H26O
Molecular Weight: 222.366
Flash Point: 113.2±15.6 °C
Exact Mass: 222.198364
PSA: 20.23000
LogP: 5.07
Vapour Pressure: 0.0±1.5 mmHg at 25°C
Index of Refraction: 1.494
Stability: Stable. Combustible. Incompatible with strong oxidizing agents.
 
Specification
Appearance: Colorless to straw yellow viscous liquid
Assay: ≥98.0%
Loss on drying: ≤0.5%
Residue on ignition: ≤1%
Heavy metal: ≤0.002%
 
Application
Alpha-Bisabolol is mainly used in skin protection and skin care cosmetics. Alpha-Bisabolol is used as an active ingredient to protect and care for allergic skin. Cosmetics, as well as suntan baths, baby products and post-shave care products. In addition, alpha-bisabolol is also used in oral hygiene products such as toothpaste and mouthwash.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

α-Bisabolol


Related News: According to statistics, in 2017, China’s total production of chemical drugs reached 3.478 million tons, a year-on-year increase of 1.6%. The main business income showed a steady increase, from 328.972 billion yuan in 2012 to 573.475 billion yuan in 2017. The total profit was 48.644 billion yuan, but profit margins remain low (8.48% in 2017).1246616-66-9 At present, the additional 300 tons of sunniamine, 300 tons of fluoxamic acid, and 200 tons of cyprodinil have been successfully put into production, and the profitability is good.1443-80-7 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.Metiltris (metiletilcetoxima) silano CAS:22984-54-9 The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application.

Related Products
Product Name
HYDRAZINE SULFATE Cas:10034-93-2 View Details
chloromethyl(trimethyl)silane View Details
(R)-3-Hydroxypiperidine Hydrochloride Cas:198976-43-1 View Details
3,4-epoxycyclohexylmethyl methacrylate Cas:82428-30-6 manufacturer Tris(triphenylphosphine)ruthenium(II) chloride Cas:15529-49-4 manufacturer Cefpirome Sulfate Cas:98753-19-6 manufacturer 2-Deoxy-2,2-difluoro-D-ribofuranose-3,5-dibenzoate-1-methanesulfonate Cas:134877-42-2 manufacturer DL-carnitine HCL Cas:461-05-2 manufacturer